Search results
Ipsen outlines $461m for ex-US rights to Day One’s glioma therapy
Pharmaceutical Technology· 1 day agoIpsen is looking to expand its paediatric medication portfolio and has signed a licensing agreement...
Nanotechnology in medicine: Who are the leading public companies?
Medical Device Network· 3 days agoApplications for nanotechnology in medicine include imaging, diagnosis, or the delivery of drugs...
Ariceum starts radionuclide Phase I trial in glioblastoma
Clinical Trials Arena· 1 day agoAriceum’s most advanced asset is the Phase II candidate SS0110 – beta-emitting lutetium-177...
Evolus’s ‘frown line’ treatment Jeuveau could threaten Botox revenues
Pharmaceutical Technology· 3 days agoEvolus’ Jeuveau (DWP-450) (prabotulinumtoxinA) will likely prove to be a strong competitor to...